BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ivens IA, Baumann A, Mcdonald TA, Humphries TJ, Michaels LA, Mathew P. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia 2013;19:11-20. [DOI: 10.1111/j.1365-2516.2012.02931.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Tabriznia-Tabrizi S, Gholampour M, Mansouritorghabeh H. A close insight to factor VIII inhibitor in the congenital hemophilia A. Expert Rev Hematol 2016;9:903-13. [PMID: 27367203 DOI: 10.1080/17474086.2016.1208554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Shapiro AD. Long-lasting recombinant factor VIII proteins for hemophilia A. Hematology Am Soc Hematol Educ Program 2013;2013:37-43. [PMID: 24319160 DOI: 10.1182/asheducation-2013.1.37] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
3 Balkaransingh P, Young G. Novel therapies and current clinical progress in hemophilia A. Ther Adv Hematol 2018;9:49-61. [PMID: 29387330 DOI: 10.1177/2040620717746312] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
4 Cafuir LA, Kempton CL. Current and emerging factor VIII replacement products for hemophilia A. Ther Adv Hematol 2017;8:303-13. [PMID: 29051801 DOI: 10.1177/2040620717721458] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
5 Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014;12:488-96. [PMID: 24843882 DOI: 10.1111/jth.12506] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 13.6] [Reference Citation Analysis]
6 Lu Y, Xiao Y, Yin MZ, Zhou XC, Wu LS, Chen WQ, Luo Y, Kuang YH, Zhu W. Polyethylene Glycol Ointment Alleviates Psoriasis-Like Inflammation Through Down-Regulating the Function of Th17 Cells and MDSCs. Front Med (Lausanne) 2020;7:560579. [PMID: 33834028 DOI: 10.3389/fmed.2020.560579] [Reference Citation Analysis]
7 Lambert T, Benson G, Dolan G, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Zupančić-Šalek S, Santagostino E. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol 2018;9:295-308. [PMID: 30210757 DOI: 10.1177/2040620718796429] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
8 Powell JS. Lasting power of new clotting proteins. Hematology Am Soc Hematol Educ Program 2014;2014:355-63. [PMID: 25696879 DOI: 10.1182/asheducation-2014.1.355] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lim MY. How do we optimally utilize factor concentrates in persons with hemophilia? Hematology Am Soc Hematol Educ Program 2021;2021:206-14. [PMID: 34889393 DOI: 10.1182/hematology.2021000310] [Reference Citation Analysis]
10 Awwad S, Ginn C, Brocchini S. The case for protein PEGylation. Engineering of Biomaterials for Drug Delivery Systems. Elsevier; 2018. pp. 27-49. [DOI: 10.1016/b978-0-08-101750-0.00002-7] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
11 Binder U, Skerra A. Current Strategies for Pharmacokinetic Optimization. In: Rosenberg A, Demeule B, editors. Biobetters. New York: Springer; 2015. pp. 269-311. [DOI: 10.1007/978-1-4939-2543-8_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
12 Ternisien C, Lasne D, Grand F, Harzallah I, Jeanpierre E, Repesse Y, Ryman A, Sapin AF, Voisin S, Nougier C, Pouplard C; French study group on laboratory management of bleeding disorders (BIMHO Group-GFHT). Impact of aPTT reagents on measurement of a PEGylated recombinant FVIII (Adynovi® /Adynovate® ): A French multicentric field assay study. Int J Lab Hematol 2021. [PMID: 34559452 DOI: 10.1111/ijlh.13707] [Reference Citation Analysis]
13 Shah A, Coyle T, Lalezari S, Fischer K, Kohlstaedde B, Delesen H, Radke S, Michaels LA. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies. Haemophilia 2018;24:733-40. [DOI: 10.1111/hae.13561] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
14 Escobar M, Santagostino E, Mancuso ME, Coppens M, Balasa V, Taylor JA, Iorio A, Negrier C. Switching patients in the age of long-acting recombinant products? Expert Rev Hematol 2019;12:1-13. [PMID: 31282771 DOI: 10.1080/17474086.2018.1564032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
15 Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs. J Pharm Sci. 2016;105:460-475. [PMID: 26869412 DOI: 10.1016/j.xphs.2015.11.015] [Cited by in Crossref: 357] [Cited by in F6Publishing: 307] [Article Influence: 59.5] [Reference Citation Analysis]
16 Jair Lara-navarro I, Rebeca Jaloma-cruz A. Current Therapies in Hemophilia: From Plasma-Derived Factor Modalities to CRISPR/Cas Alternatives. Tohoku J Exp Med 2022;256:197-207. [DOI: 10.1620/tjem.256.197] [Reference Citation Analysis]
17 Stidl R, Fuchs S, Bossard M, Siekmann J, Turecek PL, Putz M. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates. Haemophilia 2016;22:54-64. [PMID: 26219204 DOI: 10.1111/hae.12762] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
18 Lassila R, Makris M. Safety surveillance in haemophilia and allied disorders. J Intern Med 2016;279:515-23. [PMID: 27001233 DOI: 10.1111/joim.12456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sternebring O, Christensen JK, Bjørnsdottir I. Pharmacokinetics, tissue distribution, excretion, and metabolite profiling of PEGylated rFIX (nonacog beta pegol, N9-GP) in rats. European Journal of Pharmaceutical Sciences 2016;92:163-72. [DOI: 10.1016/j.ejps.2016.06.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
20 Kizilocak H, Young G. Emerging drugs for hemophilia A: insights into phase II and III clinical trials. Expert Opin Emerg Drugs 2021;26:337-50. [PMID: 34601977 DOI: 10.1080/14728214.2021.1988073] [Reference Citation Analysis]
21 de Castro C, Grossi F, Weitz IC, Maciejewski J, Sharma V, Roman E, Brodsky RA, Tan L, Di Casoli C, El Mehdi D, Deschatelets P, Francois C. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol 2020;95:1334-43. [PMID: 33464651 DOI: 10.1002/ajh.25960] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
22 Barnes C. Recent Advances in Haemophilia Management. Curr Pediatr Rep 2015;3:154-9. [DOI: 10.1007/s40124-015-0080-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for hemophilia. Blood 2013;122:3568-74. [PMID: 24065241 DOI: 10.1182/blood-2013-07-498261] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
24 Blaich G, Baumann A, Kronenberg S, de Haan L, Ulrich P, Richter WF, Tibbitts J, Chivers S, Tarcsa E, Caldwell R, Crameri F. Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new Insights. Regul Toxicol Pharmacol 2016;80S:S1-S14. [PMID: 27578450 DOI: 10.1016/j.yrtph.2016.08.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
25 Shapiro A. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opinion on Biological Therapy 2013;13:1287-97. [DOI: 10.1517/14712598.2013.819339] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
26 Astermark J, Dolan G, Hilberg T, Jiménez-Yuste V, Laffan M, Lassila R, Lobet S, Martinoli C, Perno CF. Managing haemophilia for life: 4th Haemophilia Global Summit. Haemophilia 2014;20 Suppl 5:1-20. [PMID: 24924596 DOI: 10.1111/hae.12468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
27 Schneeweis LA, Obenauer-Kutner L, Kaur P, Yamniuk AP, Tamura J, Jaffe N, O'Mara BW, Lindsay S, Doyle M, Bryson J. Comparison of Ensemble and Single Molecule Methods for Particle Characterization and Binding Analysis of a PEGylated Single-Domain Antibody. J Pharm Sci 2015;104:4015-24. [PMID: 26343417 DOI: 10.1002/jps.24624] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Baumann A, Piel I, Hucke F, Sandmann S, Hetzel T, Schwarz T. Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction. European Journal of Pharmaceutical Sciences 2019;130:11-20. [DOI: 10.1016/j.ejps.2019.01.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
29 Fletcher AM, Tellier P, Douville J, Mansell P, Graziano MJ, Mangipudy RS, Brodie TA, Achanzar WE. Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein. Toxicology Letters 2019;317:120-9. [DOI: 10.1016/j.toxlet.2019.09.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
30 Baumann A, Tuerck D, Prabhu S, Dickmann L, Sims J. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? Drug Discov Today 2014;19:1623-31. [PMID: 24929223 DOI: 10.1016/j.drudis.2014.06.002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 10.3] [Reference Citation Analysis]
31 Pruthi RK. Laboratory monitoring of new hemostatic agents for hemophilia. Semin Hematol 2016;53:28-34. [PMID: 26805904 DOI: 10.1053/j.seminhematol.2015.10.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
32 Mannucci PM, Mancuso ME, Franchini M. Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A. J Thromb Haemost 2016;14:1330-6. [PMID: 27155314 DOI: 10.1111/jth.13356] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
33 Ibeanu N, Egbu R, Onyekuru L, Javaheri H, Khaw PT, Williams GR, Brocchini S, Awwad S. Injectables and Depots to Prolong Drug Action of Proteins and Peptides. Pharmaceutics 2020;12:E999. [PMID: 33096803 DOI: 10.3390/pharmaceutics12100999] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Paik J, Deeks ED. Damoctocog Alfa Pegol: A Review in Haemophilia A. Drugs 2019;79:1147-56. [PMID: 31218660 DOI: 10.1007/s40265-019-01152-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
35 Gu J, Ramsey P, Evans V, Tang L, Apeler H, Leong L, Murphy JE, Laux V, Myles T. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia 2014;20:593-600. [DOI: 10.1111/hae.12374] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]
36 Morfini M, Rapisarda CAP. Safety of recombinant coagulation factors in treating hemophilia. Expert Opin Drug Saf 2019;18:75-85. [PMID: 30681006 DOI: 10.1080/14740338.2019.1574743] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Huckaby JT, Jacobs TM, Li Z, Perna RJ, Wang A, Nicely NI, Lai SK. Structure of an anti-PEG antibody reveals an open ring that captures highly flexible PEG polymers. Commun Chem 2020;3. [DOI: 10.1038/s42004-020-00369-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
38 Hartmann J, Croteau SE. 2017 Clinical trials update: Innovations in hemophilia therapy. Am J Hematol 2016;91:1252-60. [PMID: 27563744 DOI: 10.1002/ajh.24543] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 10.0] [Reference Citation Analysis]
39 Powell JS. Longer-acting clotting factor concentrates for hemophilia. J Thromb Haemost 2015;13:S167-75. [DOI: 10.1111/jth.12912] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
40 Ivens IA, Achanzar W, Baumann A, Brändli-Baiocco A, Cavagnaro J, Dempster M, Depelchin BO, Rovira AR, Dill-Morton L, Lane JH, Reipert BM, Salcedo T, Schweighardt B, Tsuruda LS, Turecek PL, Sims J. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development. Toxicol Pathol 2015;43:959-83. [PMID: 26239651 DOI: 10.1177/0192623315591171] [Cited by in Crossref: 95] [Cited by in F6Publishing: 85] [Article Influence: 13.6] [Reference Citation Analysis]
41 Franchini M, Frattini F, Crestani S, Sissa C, Bonfanti C. Treatment of hemophilia B: focus on recombinant factor IX. Biologics 2013;7:33-8. [PMID: 23430394 DOI: 10.2147/BTT.S31582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
42 Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for hemophilia. Hematology Am Soc Hematol Educ Program 2013;2013:30-6. [PMID: 24319159 DOI: 10.1182/asheducation-2013.1.30] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
43 Sørensen MH, Andersen S, Ezban M. Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays. Haemophilia 2015;21:832-6. [DOI: 10.1111/hae.12680] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
44 Arruda VR, Doshi BS, Samelson-Jones BJ. Novel approaches to hemophilia therapy: successes and challenges. Blood 2017;130:2251-6. [PMID: 29018078 DOI: 10.1182/blood-2017-08-742312] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 11.2] [Reference Citation Analysis]
45 Mahlangu J. An update of the current pharmacotherapeutic armamentarium for hemophilia A. Expert Opin Pharmacother 2021;:1-10. [PMID: 34404300 DOI: 10.1080/14656566.2021.1961742] [Reference Citation Analysis]
46 Mannucci PM. Hemophilia therapy: the future has begun. Haematologica 2020;105:545-53. [PMID: 32060150 DOI: 10.3324/haematol.2019.232132] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 16.5] [Reference Citation Analysis]
47 Mannucci PM. Half-life extension technologies for haemostatic agents. Thromb Haemost 2015;113:165-76. [PMID: 25274414 DOI: 10.1160/TH14-04-0332] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
48 Meunier S, Alamelu J, Ehrenforth S, Hanabusa H, Abdul Karim F, Kavakli K, Khodaie M, Staber J, Stasyshyn O, Yee DL, Rageliene L. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost 2017;117:1705-13. [PMID: 28692108 DOI: 10.1160/TH17-03-0166] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 6.2] [Reference Citation Analysis]
49 Katre NV. Site-specific polymer–protein conjugates by Cys mutation. Polymer-Protein Conjugates. Elsevier; 2020. pp. 297-316. [DOI: 10.1016/b978-0-444-64081-9.00014-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Bossard MJ. PEG–protein conjugates; regulatory requirements for characterization. Polymer-Protein Conjugates. Elsevier; 2020. pp. 141-54. [DOI: 10.1016/b978-0-444-64081-9.00007-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus 2019;17:479-86. [PMID: 31846611 DOI: 10.2450/2019.0211-19] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
52 Holm LS, Thulstrup PW, Kasimova MR, van de Weert M. Preferential Interactions and the Effect of Protein PEGylation. PLoS One 2015;10:e0133584. [PMID: 26230338 DOI: 10.1371/journal.pone.0133584] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
53 Windyga J, Abbuehl BE, Hafeman AE. BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B. Expert Review of Hematology 2014;7:333-42. [DOI: 10.1586/17474086.2014.903153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
54 Lubich C, Allacher P, de la Rosa M, Bauer A, Prenninger T, Horling FM, Siekmann J, Oldenburg J, Scheiflinger F, Reipert BM. The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know? Pharm Res 2016;33:2239-49. [PMID: 27271335 DOI: 10.1007/s11095-016-1961-x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 10.8] [Reference Citation Analysis]
55 Bulla O, Poncet A, Alberio L, Asmis LM, Gähler A, Graf L, Nagler M, Studt JD, Tsakiris DA, Fontana P. Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study. Haemophilia 2017;23:e335-9. [PMID: 28544263 DOI: 10.1111/hae.13250] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
56 Mahlangu J. rFVIIIFC for hemophilia A prophylaxis. Expert Rev Hematol 2018;11:937-43. [PMID: 30449223 DOI: 10.1080/17474086.2018.1549478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
57 Ivens IA, Banczyk D, Gutberlet K, Jackman S, Vauléon S, Frisk AL. Nonclinical Safety Assessment of a Long-Acting Recombinant PEGylated Factor Eight (BAY 94-9027) With a 60 kDa PEG. Toxicol Pathol 2019;47:585-97. [PMID: 31132933 DOI: 10.1177/0192623319852300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Turecek PL, Siekmann J. PEG–protein conjugates. Polymer-Protein Conjugates. Elsevier; 2020. pp. 61-101. [DOI: 10.1016/b978-0-444-64081-9.00004-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Arruda VR, Doshi BS, Samelson-Jones BJ. Emerging therapies for hemophilia: controversies and unanswered questions. F1000Res 2018;7:F1000 Faculty Rev-489. [PMID: 29770199 DOI: 10.12688/f1000research.12491.1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
60 Palesch D, Boldt F, Müller JA, Eisele K, Stürzel CM, Wu Y, Münch J, Weil T. PEGylated Cationic Serum Albumin for Boosting Retroviral Gene Transfer. Chembiochem 2016;17:1504-8. [PMID: 27239020 DOI: 10.1002/cbic.201600193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
61 Bjørnsdottir I, Sternebring O, Kappers WA, Selvig H, Kornø HT, Kristensen JB, Bagger MA. Pharmacokinetics, tissue distribution and excretion of 40kDa PEG and PEGylated rFVIII (N8-GP) in rats. European Journal of Pharmaceutical Sciences 2016;87:58-68. [DOI: 10.1016/j.ejps.2015.10.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
62 Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia 2014;20:99-105. [DOI: 10.1111/hae.12405] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
63 Turecek PL, Abbühl B, Tangada SD, Chapman M, Gritsch H, Rottensteiner H, Schrenk G, Mitterer A, Dietrich B, Höllriegl W, Schiviz A, Horling F, Reipert BM, Muchitsch EM, Pavlova BG, Scheiflinger F. Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes. Expert Rev Clin Pharmacol 2015;8:163-77. [PMID: 25660348 DOI: 10.1586/17512433.2015.1011126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
64 Englert C, Brendel JC, Majdanski TC, Yildirim T, Schubert S, Gottschaldt M, Windhab N, Schubert US. Pharmapolymers in the 21st century: Synthetic polymers in drug delivery applications. Progress in Polymer Science 2018;87:107-64. [DOI: 10.1016/j.progpolymsci.2018.07.005] [Cited by in Crossref: 73] [Cited by in F6Publishing: 26] [Article Influence: 18.3] [Reference Citation Analysis]
65 Awwad S, Angkawinitwong U. Overview of Antibody Drug Delivery. Pharmaceutics 2018;10:E83. [PMID: 29973504 DOI: 10.3390/pharmaceutics10030083] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 12.3] [Reference Citation Analysis]
66 Irizarry Rovira AR, Bennet BM, Bolon B, Braendli-baiocco A, Chandra S, Fleurance R, Garman R, Hutto D, Lane J, Romeike A, Sargeant A, Zimmerman B. Scientific and Regulatory Policy Committee Points to Consider: Histopathologic Evaluation in Safety Assessment Studies for PEGylated Pharmaceutical Products. Toxicol Pathol 2018;46:616-35. [DOI: 10.1177/0192623318791801] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
67 Stidl R, Denne M, Goldstine J, Kadish B, Korakas KI, Turecek PL. Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety. Pharmaceuticals (Basel) 2018;11:E75. [PMID: 30049994 DOI: 10.3390/ph11030075] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
68 Swierczewska M, Lee KC, Lee S. What is the future of PEGylated therapies? Expert Opin Emerg Drugs 2015;20:531-6. [PMID: 26583759 DOI: 10.1517/14728214.2015.1113254] [Cited by in Crossref: 113] [Cited by in F6Publishing: 97] [Article Influence: 16.1] [Reference Citation Analysis]
69 Laffan M. New products for the treatment of haemophilia. Br J Haematol 2016;172:23-31. [PMID: 26456702 DOI: 10.1111/bjh.13797] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
70 McEneny-King A, Iorio A, Foster G, Edginton AN. The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opin Drug Metab Toxicol 2016;12:1313-21. [PMID: 27539370 DOI: 10.1080/17425255.2016.1214711] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
71 Chowdary P. Extended half-life recombinant products in haemophilia clinical practice - Expectations, opportunities and challenges. Thromb Res 2020;196:609-17. [PMID: 31883700 DOI: 10.1016/j.thromres.2019.12.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
72 Rasmussen CE, Nowak J, Larsen JM, Moore E, Bell D, Liu KC, Sorensen NS, Kappers WA, Krogh-Meibom T, Offenberg H. Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat. J Toxicol 2017;2017:8496246. [PMID: 28458688 DOI: 10.1155/2017/8496246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
73 Zhao W, Liu F, Chen Y, Bai J, Gao W. Synthesis of well-defined protein–polymer conjugates for biomedicine. Polymer 2015;66:A1-A10. [DOI: 10.1016/j.polymer.2015.03.054] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
74 Ducore JM, Miguelino MG, Powell JS. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B. Expert Review of Hematology 2014;7:559-71. [DOI: 10.1586/17474086.2014.951322] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
75 Xie C, Wang Z, Su Y, Wang J, Shen WC. Discovery of An Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B. Int J Mol Sci 2019;21:E21. [PMID: 31861459 DOI: 10.3390/ijms21010021] [Reference Citation Analysis]
76 Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol 2020;99:2689-98. [PMID: 32974838 DOI: 10.1007/s00277-020-04280-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]